Medac Gesellschaft für klinische Spezialpräparate mbH (Manufacturer responsible for primary packaging labelling, secondary packaging, application of protective film (optional), batch control/testing and batch release)

The drug is intended for the treatment of advanced colorectal cancer. It is used both in combination with other drugs (5-fluorouracil, folinic acid, bevacizumab, cetuximab, or capecitabine) and as monotherapy if previous treatment has been ineffective.

Dosage form: concentrate for infusion solution

ATC: L01CE02